INDICATIONS

FORMS

*Prices represent the cost per unit specified and are representative of the "Average Wholesale Price" (AWP).
^Dosage is indicated in mg unless otherwise noted.

^^OTC: Over the counter in the US

USUAL ADULT DOSING

• Apply topically 5 times per day as soon as possible during the HSV prodromal stage.
  • Prodromal stage: pain, burning, itching, or tingling at the site where the blisters will form.
  • Later application may not be effective; use should be limited to 10 days.
  • Do not apply directly inside the mouth or to the eyes.
  • Duration: Apply 5 times daily to lesion(s) until healed.
    • Seek medical advice if not improving or if prolonged.
• Available over the counter in the U.S.

ADULT RENAL DOSING

PEDIATRIC DOSING

ADVERSE DRUG REACTIONS

DRUG INTERACTIONS

None

SPECTRUM

HSV

• FDA indication for recurrent herpes labialis/orolabial HSV, mainly HSV-1

PHARMACOLOGY

COMMENTS

• Best suited for immunocompetent patients with mild recurrent herpes labialis who want an OTC option and can start treatment at the prodrome; not a substitute for systemic therapy when episodes are severe, frequent, or atypical.
• Used against labial herpes, not genital outbreaks.
• Clinical benefit is modest, with approximately 18 hours of reduced healing time in the pivotal RCT.
  
  • The inconvenience of 5x per day administration, cost, and minimal benefit probably should limit the use of this over-the-counter (OTC) product.
• Notably, docosanol has in vitro activity against acyclovir-resistant HSV.
  • Because its mechanism differs from that of nucleoside analogues such as acyclovir, in vitro activity extends to acyclovir-resistant HSV isolates; however, clinical outcome data specifically supporting its use for acyclovir-resistant herpes labialis are limited.
  • Typically, acyclovir-resistant HSV is seen in immunocompromised patients, and topical therapy used successfully included compounded foscarnet or cidofovir.

References

1. Mancini A, Inchingolo AM, Marinelli G, et al. Topical and Systemic Therapeutic Approaches in the Treatment of Oral Herpes Simplex Virus Infection: A Systematic Review. Int J Mol Sci. 2025;26(17).  [PMID:40943411]

   Comment: A systematic review that showed the effectiveness of topical and systemic antivirals, including topical docosanol, against oral HSV infection. This is a superficial compendium without much useful insight.
   

2. Koe KH, Veettil SK, Maharajan MK, et al. COMPARATIVE EFFICACY OF ANTIVIRAL AGENTS FOR PREVENTION AND MANAGEMENT OF HERPES LABIALIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. J Evid Based Dent Pract. 2023;23(1):101778.  [PMID:36914303]

   Comment: The review found that valacyclovir plus a steroid produced the best results.
   

3. Sadowski LA, Upadhyay R, Greeley ZW, et al. Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2. Viruses. 2021;13(7).  [PMID:34202050]

   Comment: This article focuses on the mechanism of action of docosanol. A note is made that, as a primary alcohol, it has activity against acyclovir-resistant HSV.
   

4. McCarthy JP, Browning WD, Teerlink C, et al. Treatment of herpes labialis: comparison of two OTC drugs and untreated controls. J Esthet Restor Dent. 2012;24(2):103-9.  [PMID:22524716]

   Comment: The study that used a patient survey instrument reported a 4-day reduction in time to healing compared with placebo, with one arm containing docosanol.
   

5. Treister NS, Woo SB. Topical n-docosanol for management of recurrent herpes labialis. Expert Opin Pharmacother. 2010;11(5):853-60.  [PMID:20210688]

   Comment: A review of the available literature speaks to the safety of this topical compound, and given the mechanism of action, there is little chance for the development of resistance.
   

6. McKeough MB, Spruance SL. Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. Arch Dermatol. 2001;137(9):1153-8.  [PMID:11559210]

   Comment: The authors compared three topical treatments (penciclovir cream, acyclovir cream, and docosanol cream) in a guinea pig model of HSV infection. Penciclovir was superior to acyclovir cream in reducing the number of lesions (19% vs. 0%), area involved (38% vs. 21%) and virus titer (88% vs. 75%). The n-docosanol cream failed to show any differences compared to controls. The authors conclude that penciclovir cream is superior to the other two topical preparations in this animal model and presumably in people as well.
   

7. Sacks SL, Thisted RA, Jones TM, et al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol. 2001;45(2):222-30.  [PMID:11464183]

   Comment: RCT suggests ~18h improvement over placebo in median time to healing. Only mild adverse reactions were seen.
   

8. Habbema L, De Boulle K, Roders GA, et al. N-Docosanol 10% cream in the treatment of recurrent herpes labialis: a randomised, double-blind, placebo-controlled study. Acta Derm Venereol. 1996;76(6):479-81.  [PMID:8982417]

   Comment: A small RCT with a crossover design found ~3d benefit when used at the prodromal or erythema phase. Later docosanol use was similar to placebo.